⌕

GRÜNENTHAL — A WORLD FREE OF PAIN, BUILT ON THALIDOMIDE

NOV 9, 2026 · SPLASH · SOURCED FROM FERN · ALLEGATIONS LABELED
Grünenthal and the opioid trade

THE COMPANY. Grünenthal sits in Stolberg, Germany, near the Dutch border, and calls itself one of the world's leading painkiller manufacturers. Its slogan is "a world free of pain." The video puts the company at roughly $1.9 billion.

Its history is a straight line from the worst of the 20th century to the pharmacies of today.

THE LABS. Founded in 1946 by the Wirtz family — detergent money, pivoting to medicine in a ruined country — Grünenthal became the first company to sell penicillin in Germany. It also staffed its research division with men from the camps. Dr. Heinrich Mückter, its head of research, was accused of lethal experiments on concentration camp prisoners and never convicted. Heinz Baumkötter, a Sachsenhausen physician who allegedly injected inmates with hepatitis and burned their skin with phosphorus, served part of eight years and later worked for the firm. Otto Ambros, a chemical weapons expert linked to Monowitz, became an adviser in 1972.

At least five high-ranking former Nazis, by the reporting. The company confirms it employed researchers who held power in the Nazi party and says that was common practice in post-war Germany.

CONTERGAN. In 1957 Grünenthal launched thalidomide as a tranquilizer and sleeping pill, prescribed to pregnant women for morning sickness. It sold in nearly 50 countries. Then the babies came — around 12,000 documented with severe birth defects, missing or stunted limbs, and at least a third dead before their first birthday. The drug was withdrawn after four years. The Wirtz family apologized publicly in 2021 and points to its foundation as its moral obligation.

THE SECOND ACT. In 1977 the company launched Tramal — tramadol — and it became one of the most prescribed analgesics on earth. It was marketed as a weak opioid. It isn't.

THE COMMITTEE. This is the part that reads like a fix. In May 2010, Germany's federal drugs institute convened its expert committee on narcotics, with tramadol on the agenda. Stricter scheduling would mean tamper-proof prescriptions — the exact thing that would have stopped people like Marco, a 23-year-old in Berlin who printed his own scripts and died of combined tramadol intoxication.

Grünenthal wrote to the agency opposing tighter rules, warning it

“could send the rest of the world a fatal signal.”

The committee deferred, then formed a working group of eight of its twelve members to study the science.

The chair of that working group held a professorship sponsored by Grünenthal. In December 2011 the committee reported that tramadol showed no elevated risk of misuse or addiction and left it unscheduled. The agency says it was never told of conflicts that would have disqualified anyone.

The UK made tramadol a Schedule 3 controlled drug in 2014. France calls it high-risk. Canada, the US and Sweden regulate it tightly. Germany — where the drug was invented — did not.

THE SOFT PLAYBOOK. Where Purdue told doctors outright that OxyContin wasn't addictive, Grünenthal's version is quieter: fund the science, fund the societies, fund the patient groups.

Over a decade it paid more than $9 million to at least 900 European patient organizations. In Mexico, a Grünenthal-funded pain association reportedly lobbied Congress to loosen tapentadol prescribing. In Peru, the head of a similar association told a room of doctors the drug was less addictive — and, allegedly, that it could be a source of profit.

Grünenthal's own Mexican training platform hosted a video by Dr. Silvia Allende Pérez — head of a public pain clinic, and a former Grünenthal employee — with a slide claiming tapentadol's abuse potential is minimal and that there were no reports of respiratory depression. A 2017 post-market study calls respiratory depression a major clinical concern, and the package insert lists it. Confronted, the company pulled the video and acknowledged some slides were incorrect.

THE SCIENCE. A 2014 paper in CNS Drugs argued tapentadol's dual mechanism might reduce dependence. All of its authors were Grünenthal employees. Experts the journalists consulted found no evidence for the claim, and the company now concedes there isn't sufficient evidence. An internal J&J email about the same theory:

“I don't know of any evidence to support that, but I can live with the people at J&J believing this to be true.”

THE DAMAGE. Brad Foote, in Victoria, Australia, kicked oxycodone after two years and was prescribed Palexia — tapentadol — for chronic headaches. The packaging warned of higher addiction risk given his history. A year later his wife gave birth to triplets; he was drowsy, then irritable and aggressive in withdrawal. He missed the triplets' first Christmas and was asked to move out. Five months later he was dead of a tapentadol and oxycodone overdose.

In Togo, tramadol is "the poor man's cocaine" — moto taxi drivers taking two pills to survive twelve-hour shifts, supplied by generics trafficked from China and India, not by Grünenthal. Cameroonian researchers found tramadol in plants, soil and well water; a follow-up study showed it was man-made contamination, not natural.

In Germany, 1.5 to 2 million people are addicted to prescription drugs. In 2023, eight of every hundred drug deaths involved opioid painkillers — and among 14-to-20-year-olds, one in three.

SPLASH'S READ: The thalidomide scandal is famous. What's more instructive is how a company survives one — and the answer is: slowly, quietly, and by never saying the thing that gets you sued.

Purdue's crime was a sentence: "less than one percent of patients become addicted." Grünenthal's method is a budget line: a professorship here, a patient group there, a conference in Peru, a training video on its own platform. Nothing that reads as a lie in a courtroom. Everything that shapes what a doctor believes about a drug.

And the incentive structure explains the whole thing. A generic costs pennies; a branded opioid with a "cleaner" reputation can be sold at a premium for as long as the story holds. That's why the dual-mechanism paper exists, why the Mexican slides existed, and why the German committee's chair didn't recuse.

Grünenthal says it no longer plans to research new opioids, and that Palexia and Tramal are a shrinking slice of revenue. That's the honest ending — the market moved on. But 12,000 thalidomide children and a generation of tramadol addicts didn't get to move on, and "a world free of pain" was never a promise the drug could keep.

Sources & claims: fern (YouTube), "Exposing a $1,900,000,000 Pharma Company," produced with reporting from The Examination and journalists in 10 countries. Thalidomide figures (~12,000 births, a third dead by age one), the 2010–11 German committee and its chair's sponsored professorship, the $9M/900-group figure, and the case studies (Brad Foote, Marco) are as reported in the video. Grünenthal disputes framing and says it never marketed tramadol as low-risk; its responses are included. No finding of liability underlies this piece.